Showing results (101-110 of 107) with videos related to
Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 107 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2013
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysisJohn Koreth, Joseph Pidala, Waleska S Perez, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2022
Longitudinal Outcome over Two Decades of Unrelated Allogeneic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: An ALWP/EBMT AnalysisArnon Nagler, Maud Ngoya, Jacques-Emmanuel Galimard, et al.Leukemia|August 30, 2019
Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysisStefan Knop, Monika Engelhardt, Peter Liebisch, et al.Bone Marrow Transplantation|May 6, 2018
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working PartiesPeter Dreger, Mauricette Michallet, Paul Bosman, et al.Cancer|June 18, 2016
Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysisAbhinav Deol, Salyka Sengsayadeth, Kwang Woo Ahn, et al.Nature Medicine|February 13, 2018
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cellsNimitha R Mathew, Francis Baumgartner, Lukas Braun, et al.Nature Medicine|April 11, 2018
Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cellsNimitha R Mathew, Francis Baumgartner, Lukas Braun, et al.Pageof 11